Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Substance Use Disorders (SUD)

DMT for Substance Use Disorders (SUD)

31 papers and 4 clinical trials exploring dmt as a treatment for substance use disorders (sud).

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationOver 2% of the global population is affected by some form of substance use disorder, contributing to nearly 12 million deaths annually.

Substance Use Disorders (SUD)

Substance use disorders (SUDs) are complex conditions marked by compulsive substance use despite negative consequences. Recent research is exploring the therapeutic potential of various psychedelics, including LSD, psilocybin, and MDMA, in treating these disorders to provide novel, effective treatment options.

Full Substance Use Disorders (SUD) profile

Academic Research

31 papers
Open Accessindividual

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways

In a within-subject pharmacoimaging study of 11 healthy psychedelic-experienced volunteers, inhaled DMT acutely reduced connectivity between the left ventral tegmental area and the right nucleus accumbens while increasing connectivity between the nucleus accumbens and anterior cingulate cortex and between the medial prefrontal cortex and anterior cingulate. These connectivity shifts correlated with changes in volition and perception and suggest a potential therapeutic mechanism for disorders of reward processing.

Published
December 12, 2025
Journal
Scientific Reports
Authors
Lima, G., Soares, C., Teixeira, M., Pais, M., Cabral, C., Rijo, P., Castelo-Branco, M.
Paywallindividual

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics

This rat study found that zalsupindole (third-generation psychedelic) produced robust effects on structural and functional neuroplasticity in the prefrontal cortex as well as sustained antidepressant-like responses comparable to or greater than those of ketamine, psilocybin, and DMT, despite lacking any of the acute cellular and behavioural characteristics of hallucinogenic or dissociative compounds.

Published
October 13, 2025
Journal
ACS Chemical Neuroscience
Authors
Agrawal, R., Gillie, D., Mungenast, A., Chytil, M., Engel, S., Wu, M. C., Rasmussen, K., Salinas, E., Olson, D. E.
Open Accessindividual

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat

In a double-blind, placebo-controlled resting-state fMRI study of 40 meditation practitioners, buccal DMT–harmine increased functional connectivity within the visual network and between visual and attention/salience networks, whereas meditation with placebo produced greater network segregation. No prolonged disruption of cortical gradients was observed, indicating a return to typical brain organisation shortly after the experience and pointing to distinct neural mechanisms — and potential clinical complementarities — between meditation and psychedelic-augmented meditation.

Published
September 29, 2025
Journal
Imaging Neuroscience
Authors
Egger, K., Meling, D., Polat, F., Seifritz, E., Avram, M., Scheidegger, M.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
August 15, 2025
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Open Accessindividual

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

Published
April 1, 2025
Journal
EClinicalMedicine
Authors
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., Preller, K. H.

Clinical Trials

4 trials
RecruitingPhase I

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

This double-blind, randomized, placebo-controlled, parallel-group laboratory trial (n=63) conducted by Yale University aims to determine the effects of DMT (14-21mg/70kg/min) infusions, in conjunction with psychotherapy, on Alcohol Use Disorder (AUD).

Started
March 17, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06070649
CompletedPhase I

A study on the safety and effects of the drug DMT in healthy smoking individuals

Randomised, double-blind, placebo-controlled Phase I single ascending dose IV infusion study (n=50) assessing safety, PK/PD and tolerability of target-controlled DMT infusion in healthy smokers.

Started
January 8, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ISRCTN11577984
Active not recruitingPhase NA

Understanding Neuroplasticity Induced by TrYptamines (UNITy): the effects of dimethyltryptamine (DMT) on drinking

Randomised, double-blind, placebo-controlled 2×2 factorial mechanistic study (n=120) testing 25 mg IV DMT vs placebo combined with alcohol memory reactivation in non-treatment-seeking hazardous/harmful drinkers.

Started
October 30, 2020
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ISRCTN13970288
CompletedPhase NA

DPT-Assisted Psychedelic-Peak Psychotherapy for Alcoholism: An Open Clinical Study (Grof 1973, Spring Grove State Hospital)

Exploratory, open clinical study (International Pharmacopsychiatry 1973; Grof S, Soskin RA, Richards WA, Kurland AA; Spring Grove State Hospital, Baltimore, MD, USA). Participants: 51 alcoholic patients drawn from the Alcoholic Rehabilitation Unit of Spring Grove State Hospital, selected by medical and psychiatric screening for suitability for psychedelic-peak therapy. Exclusions included organic brain damage, epilepsy, active renal or hepatic disease, and other specified contraindications. Intervention: dipropyltryptamine (DPT), a synthetic short-acting psychedelic, administered as an adjunct to psychotherapy in a psychedelic-peak therapy framework. No control arm; open-label exploratory design. Outcomes: clinical and psychotherapeutic change in alcoholism. No trial registry; pre-dates any formal registration requirement by ~32 years.

Started
January 1, 1970
Type
interventional
Randomized
No
Registry ID
GROF-1973-IPP-DPT-ALCOHOL-SPRING-GROVE

Explore further

Search all DMT papers Search all Substance Use Disorders (SUD) trials Full DMT profile Full Substance Use Disorders (SUD) profile